LOWELL, Mass.--(BUSINESS WIRE)--Biometry Inc. (myBiometry), an asthma and COPD diagnostic and remote monitoring company, announced that it has successfully raised $5 million in an oversubscribed Seed funding round. The round was led by Dexcom Ventures, with participation from CareSource Indiana, Elevate Ventures, and other investor groups.

马萨诸塞州洛厄尔市。--（商业新闻短讯）--哮喘和COPD诊断和远程监测公司Biometry Inc.（myBiometry）宣布，在超额认购的种子资金回合中，该公司已成功筹集到500万美元。这一轮由Dexcom Ventures牵头，CareSource Indiana、Elevate Ventures和其他投资集团参与。

This funding will advance the development of the company’s fenoTRACK solution, a breakthrough device designed to empower asthma and COPD patients by providing data to enable early detection of exacerbations..

这笔资金将推动公司fenoTRACK解决方案的开发，fenoTRACK解决方案是一种突破性设备，旨在通过提供数据来早期发现病情恶化，从而赋予哮喘和COPD患者权力。。

“We’re excited to partner with Dexcom Ventures and CareSource as we near the milestone of submitting fenoTRACK for regulatory clearance,” said Bryan Nolan, CEO of myBiometry. “With enhanced at-home monitoring for asthma and COPD, we strive to identify attack risks sooner, enabling clinicians to offer more personalized care and preventive interventions that lessen the burden on patients, caregivers, and healthcare payers.”.

myBiometry首席执行官布莱恩·诺兰（BryanNolan）表示：“我们很高兴与Dexcom Ventures和CareSource合作，因为我们即将提交fenoTRACK进行监管审批。”。“通过加强对哮喘和COPD的家庭监测，我们努力更快地发现发作风险，使临床医生能够提供更个性化的护理和预防干预措施，减轻患者，护理人员和医疗保健付款人的负担。”。

Asthma and COPD impact over 500 million patients globally and 41 million in the US. Exacerbations, or attacks, occur in approximately 40-50% of patients annually leading to millions of ER visits and hospitalizations each year in the US alone.1-5 Frequent attacks can lead to progressive loss of lung function, permanent airway remodeling, and in COPD, death.6-8 Type 2 inflammation is the underlying driver in 80% of patients with asthma and 30-40% of patients with COPD.9-12.

哮喘和COPD影响全球超过5亿患者，美国为4100万。每年约有40-50%的患者发生恶化或发作，仅在美国每年就导致数百万急诊就诊和住院治疗。频繁发作可导致肺功能逐渐丧失，永久性气道重塑，COPD死亡[6-8]。2型炎症是80%哮喘患者和30-40%COPD患者的潜在驱动因素[9-12]。

fenoTRACK is a portable, non-invasive breath test that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO). FeNO data helps identify patients at risk of an exacerbation and tailoring therapy based on FeNO data reduces the risk of exacerbation by 38-50% in adults and children respectively.13-15.

fenoTRACK是一种便携式非侵入性呼吸测试，可通过呼出气一氧化氮（FeNO）分数测量2型气道炎症。FeNO数据有助于识别有恶化风险的患者，基于FeNO数据的定制治疗可将成人和儿童的恶化风险分别降低38-50%.13-15。

“The impact of asthma and other lung diseases on the health and wellbeing of our members of all ages cannot be overstated,” said Steve Smitherman, Regional Vice President, Midwest, at CareSource. “CareSource is constantly looking for new innovations that can help our members better manage chronic conditions, which is why we are enthusiastic about Biometry’s work and a proud investor.”.

CareSource中西部地区副总裁史蒂夫·史密瑟曼（SteveSmitherman）表示：“哮喘和其他肺部疾病对我们所有年龄段成员的健康和福祉的影响怎么强调都不为过。”。“CareSource一直在寻找新的创新，以帮助我们的成员更好地管理慢性病，这就是为什么我们对生物测量的工作充满热情，并且是一位自豪的投资者。”。

“We are thrilled to announce our investment in MyBiometry,” said Jason Halac, Senior Director from Dexcom Ventures. “Their data driven sensing solution to address chronic diseases like asthma and COPD aligns with our mission to empower people to take control of their health.'

Dexcom Ventures的高级董事杰森·哈拉克（JasonHalac）表示：“我们很高兴宣布对MyBiometry的投资。”。“他们针对哮喘和慢性阻塞性肺疾病等慢性疾病的数据驱动传感解决方案符合我们赋予人们控制健康的权力的使命。”

myBiometry is currently focused on completing the development of fenoTRACK and preparing for its regulatory submission.

myBiometry目前专注于完成fenoTRACK的开发并准备其监管提交。

About myBiometry

关于myBiometry

myBiometry’s vision is to empower people with asthma and COPD to live healthier lives by providing them with proactive and actionable data to prevent attacks at home. The company’s focus is using data for the early detection of asthma and COPD exacerbations up to 20 days in advance using intelligent diagnostics and connected monitoring.

myBiometry的愿景是通过为哮喘和COPD患者提供积极可行的数据来预防家庭发作，从而使他们能够过上更健康的生活。该公司的重点是使用智能诊断和联网监测，提前20天使用数据早期发现哮喘和COPD恶化。

Headquartered in Massachusetts, with operations in Indiana, myBiometry is at the forefront of transforming respiratory care for chronic disease patients. myBiometry’s products are currently in development and have not yet been cleared by the FDA..

myBiometry总部位于马萨诸塞州，在印第安纳州开展业务，是慢性病患者呼吸护理变革的前沿。myBiometry的产品目前正在开发中，尚未获得FDA的批准。。

For more information, please visit www.mybiometry.com.

有关更多信息，请访问www.mybiometry.com。

About Dexcom Ventures

关于Dexcom Ventures

Dexcom Ventures builds upon the foundation of excellence established by Dexcom, a leader in diabetes care technology. The venture arm focuses on investing in transformational technology platforms related to chronic disease management.

Dexcom Ventures建立在糖尿病护理技术领导者Dexcom建立的卓越基础之上。风险投资部门专注于投资与慢性病管理相关的转型技术平台。

For more information, visit www.dexcomventures.com.

For more information, visit www.dexcomventures.com.

About CareSource Indiana

关于CareSource Indiana

CareSource Indiana is a nonprofit, nationally recognized managed care organization serving over 2 million members. Since its inception in 1989, CareSource has managed one of the largest Medicaid programs in the U.S. The organization is committed to improving healthcare through initiatives focused on social determinants of health, health equity, and expanding access to care..

CareSource Indiana是一家非营利性、国家认可的管理型护理组织，服务于200多万会员。自1989年成立以来，CareSource管理着美国最大的医疗补助计划之一。该组织致力于通过关注健康的社会决定因素、健康公平和扩大获得护理的机会来改善医疗保健。。

For more information, visit www.caresource.com/in/plans.

有关更多信息，请访问www.caresource.com/in/plans。

Centers for Disease Control and Prevention. FastStats - Asthma. April 30, 2024. Accessed October 23, 2024. www.cdc.gov/nchs/fastats/asthma.htm.

疾病控制和预防中心。FastStats-哮喘。2024年4月30日。2024年10月23日访问。www.cdc.gov/nchs/fastats/asthma.htm。

Bogart M. Real-world treatment patterns and switching in COPD patients. Int J Chron Obstruct Pulmon Dis. 2023;18:1575-1586. doi:10.2147/copd.s398816.

Bogart M.COPD患者的现实世界治疗模式和转换。Int J CHON阻塞肺动脉Dis。2023年；18： 1575-1586年。doi:10.2147/copd.s398816。

Centers for Disease Control and Prevention. FastStats - Chronic Lower Respiratory Disease. April 30, 2024. Accessed October 23, 2024. www.cdc.gov/nchs/fastats/copd.htm.

疾病控制和预防中心。FastStats-慢性下呼吸道疾病。2024年4月30日。2024年10月23日访问。www.cdc.gov/nchs/fastats/copd.htm。

World Health Organization. Asthma. Accessed October 23, 2024. www.who.int/news-room/fact-sheets/detail/asthma.

世界卫生组织。哮喘。2024年10月23日访问。www.who.int/news-room/fact-sheets/detail/asthma。

Boers E, et al. Global burden of COPD through 2050. JAMA Netw Open. 2023;6(12). doi:10.1001/jamanetworkopen.2023.46598.

Boers E等人，《到2050年COPD的全球负担》。JAMA网络打开。2023年；6（12）。doi:10.1001/jamanetworkopen.2023.46598。

Kerkhof M, et al. Association between COPD exacerbations and lung function decline. Thorax. 2020;75(9):744-753. doi:10.1136/thoraxjnl-2019-214457.

Kerkhof M等人。COPD恶化与肺功能下降之间的关联。胸部。2020年；75（9）：744-753。doi:10.1136/thoraxjnl-2019-214457。

Suissa S, et al. Long-term natural history of COPD: Exacerbations and mortality. Thorax. 2012;67(11):957-963. doi:10.1136/thoraxjnl-2011-201518.

Suissa S等人。慢性阻塞性肺疾病的长期自然史：恶化和死亡率。胸部。2012年；67（11）：957-963。doi:10.1136/thoraxjnl-2011-201518。

Çolak Y, et al. Type-2 inflammation and lung function decline. Thorax. Published online January 9, 2024. doi:10.1136/thorax-2023-220972.

Çolak Y等人。2型炎症和肺功能下降。胸部。2024年1月9日在线发布。doi:10.1136/thorax-2023-220972。

Asthma & Allergy Foundation of America. Type 2 Inflammation. December 11, 2023. Accessed October 23, 2024. https://aafa.org/programs/collaborations/type-2-inflammation/.

美国哮喘和过敏基金会。2型炎症。2023年12月11日。2024年10月23日访问。https://aafa.org/programs/collaborations/type-2-inflammation/.

Vedel-Krogh S, et al. Blood eosinophils and COPD exacerbations. Am J Respir Crit Care Med. 2016;193(9):965-974. doi:10.1164/rccm.201509-1869oc.

Vedel Krogh S等人。血液嗜酸性粒细胞和COPD恶化。Am J Respir Crit Care Med。2016；193（9）：965-974。doi:10.1164/rccm.201509-1869oc。

Brightling C, et al. Airway inflammation in COPD: Precision medicine. Eur Respir J. 2019;54(2):1900651. doi:10.1183/13993003.00651-2019.

Brightling C等人。COPD中的气道炎症：精准医学。Eur Respir J.2019；54（2）：1900651。内政部：10.1183/13993003.00651-2019。

Bhatt SP, et al. Dupilumab for COPD with type 2 inflammation. N Engl J Med. 2023;389(3):205-214. doi:10.1056/nejmoa2303951.

Bhatt SP等人。Dupilumab治疗慢性阻塞性肺疾病伴2型炎症。《新英格兰医学杂志》2023年；389(3):205-214.doi:10.1056/编号2303951。

Schumann DM, et al. FeNO variability and COPD exacerbations. Respirology. 2022;28(5):445-454. doi:10.1111/resp.14439.

Schumann DM等。FeNO变异性和COPD恶化。呼吸学。2022年；28（5）：445-454。doi:10.1111/resp.14439。

Wang Z, et al. Clinical utility of FeNO in asthma management. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017.

王Z，等。FeNO在哮喘治疗中的临床应用。罗克维尔（MD）：医疗保健研究与质量机构（美国）；2017

National Heart, Lung, and Blood Institute. 2020 Asthma Management Guidelines. Accessed October 23, 2024. https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates.

国家心肺血液研究所。2020年哮喘管理指南。2024年10月23日访问。https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates.